Conroy Kevin T. - 23 Mar 2026 Form 4 Insider Report for EXACT SCIENCES CORP (EXAS)

Reporting relationship: President and CEO, Director
Issuer ticker: EXAS
Reported as of: 23 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Mar 2026, 09:20:08 UTC
Prior SEC filing: 03 Mar 2026
Next SEC filing: 28 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Kevin T. Conroy by Mark Busch, attorney-in- fact

Key filing fact

Conroy Kevin T. filed Form 4 for EXACT SCIENCES CORP (EXAS) on 23 Mar 2026.

Key facts

This page summarizes Conroy Kevin T.'s Form 4 filing for EXACT SCIENCES CORP (EXAS).
14 reported transactions and 8 derivative rows are listed below.
Accepted by SEC: 23 Mar 2026, 09:20.

Change

Previous filing in this sequence was filed on 03 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001306119 Primary reporting owner

Conroy Kevin T

Relationship: President and CEO, Director
Address: C/O EXACT SCIENCES CORP., 5505 ENDEAVOR LANE, MADISON
Signature: /s/ Kevin T. Conroy by Mark Busch, attorney-in- fact
Signature date: 23 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EXAS transaction

Common Stock

Award

Transaction value
Shares: +119,312
Change %: +9.3%
Price: $0.000000^*
Shares after: 1,397,738
Date: 23 Mar 2026
Ownership: Direct
Footnotes: F1, F2

EXAS transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -1,397,738
Change %: -100%
Price
Shares after: 0
Date: 23 Mar 2026
Ownership: Direct
Footnotes: F3

EXAS transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -29,061
Change %: -100%
Price
Shares after: 0
Date: 23 Mar 2026
Ownership: Held in 401(k) Plan
Footnotes: F3

EXAS transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -46,538
Change %: -100%
Price
Shares after: 0
Date: 23 Mar 2026
Ownership: Held in Grantor Retained Annuity Trust
Footnotes: F3

EXAS transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -86,750
Change %: -100%
Price
Shares after: 0
Date: 23 Mar 2026
Ownership: Held in Grantor Retained Annuity Trust
Footnotes: F3

EXAS transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -117,427
Change %: -100%
Price
Shares after: 0
Date: 23 Mar 2026
Ownership: Held in Grantor Retained Annuity Trust
Footnotes: F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EXAS transaction Derivative

Stock Options (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -235,388
Change %: -100%
Price
Shares after: 0
Date: 23 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 235,388
Exercise price: $21.68
Footnotes: F4, F5

EXAS transaction Derivative

Stock Options (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -66,047
Change %: -100%
Price
Shares after: 0
Date: 23 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 66,047
Exercise price: $44.37
Footnotes: F5, F8

EXAS transaction Derivative

Stock Options (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -34,110
Change %: -100%
Price
Shares after: 0
Date: 23 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 34,110
Exercise price: $92.62
Footnotes: F5, F9

EXAS transaction Derivative

Stock Options (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -100,916
Change %: -100%
Price
Shares after: 0
Date: 23 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 100,916
Exercise price: $98.18
Footnotes: F5, F10

EXAS transaction Derivative

Restricted Stock Units

Disposed to Issuer

Transaction value
Shares: -18,143
Change %: -100%
Price
Shares after: 0
Date: 23 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 18,143
Exercise price
Footnotes: F6, F7, F15

EXAS transaction Derivative

Restricted Stock Units

Disposed to Issuer

Transaction value
Shares: -44,336
Change %: -100%
Price
Shares after: 0
Date: 23 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 44,336
Exercise price
Footnotes: F6, F7, F11

EXAS transaction Derivative

Restricted Stock Units

Disposed to Issuer

Transaction value
Shares: -83,360
Change %: -100%
Price
Shares after: 0
Date: 23 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 83,360
Exercise price
Footnotes: F6, F7, F12

EXAS transaction Derivative

Restricted Stock Units

Disposed to Issuer

Transaction value
Shares: -154,829
Change %: -100%
Price
Shares after: 0
Date: 23 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 154,829
Exercise price
Footnotes: F6, F13, F14

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Conroy Kevin T. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 15 footnotes

Footnote F1

On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the "Issuer"), Abbott Laboratories, an Illinois corporation ("Parent"), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent.

Footnote F2

At the effective time of the Merger (the "Effective Time"), each performance based restricted stock unit ("PSU") outstanding as of immediately prior to the Effective Time was deemed to be fully vested, with any performance conditions deemed satisfied based on actual levels of achievement of applicable target levels as of November 19, 2025, and was cancelled and converted into the right to receive $105.00 in cash, without interest (the "Merger Consideration") in respect of each share of the Issuer's common stock, par value $0.01 per share ("Common Stock") subject to such PSU, less any applicable tax withholding.

Footnote F3

At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration.

Footnote F4

These options became exercisable in full on February 23, 2021.

Footnote F5

At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding

Footnote F6

Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock.

Footnote F7

At the Effective Time, each RSU granted under an Issuer stock plan before November 19, 2025 and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration in respect of each share of Common Stock subject to such RSU, less any applicable tax withholding.

Footnote F8

These options became exercisable on February 27, 2022.

Footnote F9

These options became exercisable on February 26, 2023.

Footnote F10

These options became exercisable on February 14, 2024.

Footnote F11

These RSUs vest in four equal annual installments beginning on February 28, 2025.

Footnote F12

These RSUs vest in four equal annual installments beginning on February 27, 2026.

Footnote F13

These RSUs vest in four equal annual installments beginning on February 25, 2027.

Footnote F14

At the Effective Time, each outstanding RSU as of immediately prior to the Effective Time that was granted on or after November 19, 2025 was assumed by Parent at the Effective Time as a Parent restricted stock unit on substantially the same terms and conditions as were applicable to the corresponding RSU (including with respect to double-trigger vesting protections), with the number of Parent common shares underlying such Parent restricted stock unit determined based on the Merger Consideration divided by the average closing price of a Parent common share for the 10 consecutive trading days ending on and including the trading day immediately preceding the Effective Time.

Footnote F15

These RSUs vest in four equal annual installments beginning on February 28, 2024.